Bornstein Sheila, Moschetta Michele, Kawano Yawara, Sacco Antonio, Huynh Daisy, Brooks Daniel, Manier Salomon, Fairfield Heather, Falank Carolyne, Roccaro Aldo M, Nagano Kenichi, Baron Roland, Bouxein Mary, Vary Calvin, Ghobrial Irene M, Rosen Clifford J, Reagan Michaela R
Maine Medical Center Research Institute, Scarborough, Maine 04074.
Dana-Farber Cancer Institute, Boston, Massachusetts 02115.
Endocrinology. 2017 Oct 1;158(10):3369-3385. doi: 10.1210/en.2017-00299.
Obesity during maturation can affect the growing skeleton directly and indirectly, although these effects and the mechanisms behind them are not fully understood. Our objective was to determine how a high-fat diet with or without metformin treatment affects skeletal development. We also sought to characterize changes that occur in white adipose tissue, circulating metabolites, lipids, and gut microbiota. A diet-induced obesity C57BL/6J mouse model was used to test the effects of obesity and metformin on bone using bone histomorphometry and microcomputed tomography. Bone marrow adipose tissue was quantified with osmium tetroxide microcomputed tomography and histology. Dual-energy x-ray absorptiometry was used to analyze body composition. Hematoxylin and eosin staining was used to assess changes in white adipose depots, mass spectrometry was used for circulating lipids and protein metabolite analysis, and ribosomal RNA sequencing was used for gut microbiome analysis. Mice fed a high fat-diet since wean displayed increased medullary areas and decreased osteoblast numbers in the long bones; this phenotype was partially normalized by metformin. Marrow and inguinal adipose expansion was also noted in obese mice, and this was partially normalized by metformin. A drug-by-diet interaction was noted for circulating lipid molecules, protein metabolites, and gut microbiome taxonomical units. Obesity was not detrimental to trabecular bone in growing mice, but bone marrow medullary expansion was observed, likely resulting from inhibition of osteoblastogenesis, and this was partially reversed by metformin treatment.
成熟过程中的肥胖会直接或间接地影响正在生长的骨骼,尽管这些影响及其背后的机制尚未完全明确。我们的目标是确定高脂饮食(无论是否接受二甲双胍治疗)如何影响骨骼发育。我们还试图描述白色脂肪组织、循环代谢物、脂质和肠道微生物群中发生的变化。采用饮食诱导的肥胖C57BL/6J小鼠模型,使用骨组织形态计量学和微型计算机断层扫描来测试肥胖和二甲双胍对骨骼的影响。用四氧化锇微型计算机断层扫描和组织学方法对骨髓脂肪组织进行定量。使用双能X线吸收法分析身体成分。苏木精和伊红染色用于评估白色脂肪库的变化,质谱用于循环脂质和蛋白质代谢物分析,核糖体RNA测序用于肠道微生物组分析。自断奶起就喂食高脂饮食的小鼠,其长骨的髓腔面积增加,成骨细胞数量减少;二甲双胍部分纠正了这种表型。肥胖小鼠还出现了骨髓和腹股沟脂肪增多的情况,二甲双胍部分纠正了这一现象。在循环脂质分子、蛋白质代谢物和肠道微生物组分类单元方面发现了饮食与药物的相互作用。肥胖对生长中小鼠的小梁骨并无损害,但观察到骨髓髓腔扩张,这可能是由于成骨细胞生成受到抑制所致,而二甲双胍治疗可部分逆转这种情况。